Home > Insider Trading > Filing (0000805928-23-000007)

Filing Details

Accession Number:: 0000805928-23-000007
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-27 17:53:52
Reporting Period:: 2023-01-25

Accepted Time:: 2023-01-27 17:53:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
805928	Axogen Inc.	AXGN	Electromedical & Electrotherapeutic Apparatus (3845)	411301878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222357	J Peter Mariani	111 W Oak Ave. Suite 500 Tampa FL 33602	Evp & Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-25	20,939	$5.04	63,047	No	4	M	Direct
Common Stock	Disposition	2023-01-25	20,939	$10.23	42,108	No	4	S	Direct
Common Stock	Acquisiton	2023-01-26	20,939	$5.04	63,047	No	4	M	Direct
Common Stock	Disposition	2023-01-26	20,939	$9.90	42,108	No	4	S	Direct
Common Stock	Acquisiton	2023-01-27	20,940	$5.04	63,048	No	4	M	Direct
Common Stock	Disposition	2023-01-27	20,940	$10.16	42,108	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to purchase)	Disposition	2023-01-25	20,939	$0.00	20,939	$5.04
Common Stock	Employee Stock Option (right to purchase)	Disposition	2023-01-26	20,939	$0.00	20,939	$5.04
Common Stock	Employee Stock Option (right to purchase)	Disposition	2023-01-27	20,940	$0.00	20,940	$5.04

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
104,697	2020-03-01	2023-03-01	No	4	M	Direct
83,758	2020-03-01	2023-03-01	No	4	M	Direct
62,818	2020-03-01	2023-03-01	No	4	M	Direct

Footnotes

The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.76 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.61 to $10.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.